Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Apalutamide/ADT Demonstrate s 100% Biochemical RFS Rate in High-Risk Prostate Cancer
FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer
FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
Garje Elucidates Biomarker-Driven Approaches Generating Excitement in Metastatic Prostate Cancer
Comparable Germline Variant Rates Seen Across Racial Groups in Metastatic Prostate Cancer
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
Extended Lymphadenectomy Shows No DFS, OS Benefit During Radical Cystectomy in Urothelial Cancer